Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.
Unfortunately for shareholders of Coherus BioSciences (NASDAQ: CHRS), that's what happened to their company after market hours last Friday. Following that, its stock price was falling by 10% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence. Among these incoming S&P SmallCap 600 constituents are pizza slinger Papa John's International, storied athletic apparel retailer Foot Locker, and JetBlue Airways.
Shares of Coherus BioSciences (NASDAQ: CHRS) soared 17.7% on Thursday, according to data provided by S&P Global Market Intelligence, after the biotech company announced better-than-expected quarterly results. Coherus' net revenue climbed a whopping 81% year over year to $58.7 million, translating to an adjusted net loss of $32.8 million, or $0.38 per share. Analysts, on average, were anticipating a wider net loss of $0.48 per share on lower revenue of $50.5 million.